A migraine disease management program in the primary care setting: Impact on patient quality of life and productivity loss

Journal of Clinical Outcomes Management

Volumn 14, Issue 6, 2007, Pages 332-338

  Kwong, Winghan Jacqueline ^a   Landy, Stephen H ^b   Braverman Panza, Jill ^c   Rosen, Jonathan H ^d   Hutchinson, Susan ^e   Burch, Steven P ^f  

^a UNIVERSITY OF GEORGIA   (United States)

^b Wesley Headache and Neurology Clinic   (United States)

^c Braverman Panza Medical Group   (United States)

^d ProHealth Physicians Inc   (United States)

^e Women's Medical Group of Irvine   (United States)

^f GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTIMIGRAINE AGENT; NARCOTIC AGENT; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; TRIPTAN DERIVATIVE;

ABSENTEEISM; ADD ON THERAPY; ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL ASSESSMENT; HEADACHE; HEADACHE IMPACT TEST; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MIGRAINE SPECIFIC QUALITY OF LIFE QUESTIONNAIRE; PRIMARY MEDICAL CARE; PRODUCTIVITY; QUALITY OF LIFE; QUESTIONNAIRE; SCHOOL; SCORING SYSTEM; SYMPTOM; TREATMENT OUTCOME; WORK;

EID: 36649028031     PISSN: 10796533     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41:646-57.
2. Osterhaus JT, Townsend RJ, Gandek B, et al. Measuring the functional status and well-being of patients with migraine headache. Headache 1994;34:337-43.
3. Schwartz BS, Stewart WF, Lipton RB. Lost workdays and decreased work effectiveness associated with headache in the workplace. J Occup Environ Med 1997;39:320-7.
4. Stang PE, Osterhaus JT. Impact of migraine in the United States: data from the National Health Interview Survey. Headache 1993;33:29-35.
5. Smith R. Impact of migraine on the family. Headache 1998; 38:423-6.
6. Burton WN, Conti DJ, Chen CY, et al. The economic burden of lost productivity due to migraine headache: a specific worksite analysis. J Occup Environ Med 2002;44:523-9.
7. Clouse JC, Osterhaus JT. Healthcare resource use and costs associated with migraine in a managed healthcare setting. Ann Pharmacother 1994;28:659-64.
8. Stang P, Cady R, Batenhorst A, Hoffman L. Workplace productivity: a review of the impact of migraine and its treatment. Pharmacoeconomics 2001;19:231-44.
9. Hu XH, Markson LE, Lipton RB, et al. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999;159:813-8.
10. Mannix LK. Epidemiology and impact of primary headache disorders. Med Clin North Am 2001;85:887-95.
11. Mathew NT. Pathophysiology, epidemiology, and impact of migraine. Clin Cornerstone 2001;4:1-17.
12. Lipton RB, Diamond S, Reed M, et al. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001;41:638-45.
13. Tepper SJ, Dahlof CG, Dowson A, et al. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the Landmark Study. Headache 2004;44:856-64.
14. De Diego EV, Lanteri-Minet M. Recognition and management of migraine in primary care: influence of functional impact measured by the headache impact test (HIT). Cephalalgia 2005; 25:184-90.
15. Harpole LH, Samsa GP, Matchar DB, et al. Burden of illness and satisfaction with care among patients with headache seen in a primary care setting. Headache 2005;45:1048-55.
16. Landy S, Kwong WJ, Roselli A, et al. Effectiveness of an education-based Migraine Care Program in improving awareness of migraine in primary care setting [abstract]. Headache 2005;45:798.
17. Landy SH, Kwong WJ, Hutchinson S, et al. Migraine: A better way to recognize and treat it. J Fam Pract 2006;55:1038-47.
18. Kwong WJ, Landy S, Hutchinson S, et al. Evaluation of primary care provider perception of headache management after participating in an education-based Migraine Care Program [abstract]. Headache 2005;45:798-9.
19. The international classification of headache disorders: 2nd edition. Headache Classification Committee of the International Headache Society. Cephalalgia 2004;24 Suppl 1:9-160.
20. Kosinski M, Bayliss MS, Bjorner JB, et al. Six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 2003;12:963-74.
21. Martin BC, Pathak DS, Sharfman MI, et al. Validity and reliability of the migraine-specific quality of life questionnaire (MSQ Version 2.1). Headache 2000;40:204-15.
22. Ondo WG, Gollomp S, Galvez-Jimenez N. A pilot study of botulinum toxin A for headache in cervical dystonia. Headache 2005;45:1073-7.
23. Kawata AK, Coeytaux RR, Devellis RF, et al. Psychometric properties of the HIT-6 among patients in a headache-specialty practice. Headache 2005;45:638-43.
24. Nachit-Ouinekh F, Dartigues JF, Henry P, et al. Use of the headache impact test (HIT-6) in general practice: relationship with quality of life and severity. Eur J Neurol 2005;12:189-93.
25. Weaver MB, Mackowiak JI, Solari PG. Triptan therapy impacts health and productivity. J Occup Environ Med 2004; 46:812-7.
26. Diamond M, Dahlof C, Papadopoulos G, et al. Topiramate improves health-related quality of life when used to prevent migraine. Headache 2005;45:1023-30.
27. Lofland JH, Johnson NE, Batenhorst AS, Nash DB. Changes in resource use and outcomes for patients with migraine treated with sumatriptan: a managed care perspective. Arch Intern Med 1999;159:857-63.
28. Cohen JA, Beall D, Beck A, et al. Sumatriptan treatment for migraine in a health maintenance organization: economic, humanistic, and clinical outcomes. Clin Ther 1999;21:190-204.
29. Adelman JU, Sharfman M, Johnson R, et al. Impact of oral sumatriptan on workplace productivity, health-related quality of life, healthcare use, and patient satisfaction with medication in nurses with migraine. Am J Manag Care 1996;2:1407-16.
30. Schulman EA, Cady RK, Henry D, et al. Effectiveness of sumatriptan in reducing productivity loss due to migraine: results of a randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2000;75:782-9.
31. Cady RC, Ryan R, Jhingran P, et al. Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebo-controlled trial. Arch Intern Med 1998; 158:1013-8.
32. Barbanti P, Carpay JA, Kwong WJ, et al. Effects of a fast disintegrating/rapid release oral formulation of sumatriptan on functional ability in patients with migraine. Curr Med Res Opin 2004;20:2021-9.
33. Kwong WJ, Taylor FR, Adelman JU. The effect of early intervention with sumatriptan tablets on migraine-associated productivity loss. J Occup Environ Med 2005;47:1167-73.
34. Maizels M, Saenz V, Wirjo J. Impact of a group-based model of disease management for headache. Headache 2003;43:621-7.
35. Lipton RB, Dodick D, Sadovsky R, et al. A self-administered screener for migraine in primary care: the ID Migraine validation study. Neurology 2003;61:375-82.